Harnessing the power of the immune system to recognize and eliminate cancer cells is a
longtime exploration. In the past decade, monoclonal antibody (mAb)-based immune …

Immune checkpoint blockade (ICB) therapies such as anti-programmed death 1 (PD-1) and
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …

With the successful treatment of B-cell lymphomas using rituximab, a monoclonal antibody
targeting CD20, novel immunotherapies have developed rapidly in recent years. Immune …

Chimeric antigen receptor (CAR) T cell therapy represents the first US Food and Drug
Administration approved gene therapy and these engineered cells function with …

New advances in the design and manufacture of monoclonal antibodies, bispecific T cell
engagers, and antibody-drug conjugates make the antibody-directed agents more powerful …

Immune checkpoint blockade has revolutionized the treatment of cancer, with impressive
responses seen in a broad variety of tumor types. Blockade of immune checkpoints and …

Immunotherapy has become an established pillar of cancer treatment improving the
prognosis of many patients with a broad variety of hematological and solid malignancies …

Checkpoint blocking antibodies targeting regulatory molecules on T cells such as CTLA-4
and PD-1 have reinvigorated the field of cancer immunotherapy. These agents have …

Checkpoint blockade (CPB) therapy can elicit durable clinical responses by reactivating an
exhausted immune response. However, response rates remain limited, likely secondary to a …

The development of immune checkpoint inhibitors represents a major breakthrough in the
field of cancer therapeutics. Pursuant to their success in melanoma and numerous solid …